AMGEN[®] Ventures

About Us

Amgen, the parent company of Amgen Ventures, has always appreciated the importance of funding early-stage innovation. Amgen was founded in 1980 by a small group of enterprising venture capitalists and scientists who saw the promise of emerging research in genetics. Since then, Amgen has grown to be a leading biotechnology company that has reached millions of patients with its medicines.

Since 2004, Amgen Ventures has invested in emerging companies to advance promising medicines and technologies supporting Amgen's mission to treat patients with serious illnesses.

Working With Amgen Ventures

In addition to capital, Amgen can provide innovators access to deep expertise and strategic insights including:

- Technical expertise across multiple therapeutic modalities
- · Strong biological and translational research
- Extensive experience conducting large-scale clinical trials
- · Expertise in biologics manufacturing and drug delivery
- · Commercial infrastructure to market medicines globally

Investment Framework

- We support innovation and build relationships in areas of great future promise complementing our strategic interest and supporting our therapeutic pipeline.
- Our investments include therapeutics and technologies to support R&D and digital health / healthcare IT.
- We invest in early and late stage companies including seed stage investments.
- Our typical size of investment is ~\$5M with up to ~\$15M reserved for the life of the company.

Focused Areas of Interest

Amgen seeks opportunities that match our strategy and expand our capabilities in oncology, immune-oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. Technologies include discovery research, digital health, health IT and drug delivery.

Portfolio Companies

Therapeutics and Drug Discovery Platforms






































Selected Exits























